ReviewNutrients2020
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical.
Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Portal hypertension mortality in the United States (1999-2023): Insights from the CDC WONDER database.Medicine · 2026Article
- Characterization and statistical lipid optimization of an oleaginous soil fungus, Gongronella butleri HMA-10: a promising novel source for sustainable lipid production.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Effect of Heterologous Expression of Key Enzymes Involved in Astaxanthin and Lipid Synthesis on Lipid and Carotenoid Production inMarine drugs · 2025Article
- Dietary isobutyric acid supplementation improves intestinal mucosal barrier function and meat quality by regulating cecal microbiota and serum metabolites in weaned piglets.Frontiers in veterinary science · 2025Article
- Shizao decoction for cirrhotic ascites: assessing potential targets based on network analysis combined with pharmacokinetics and metabolomics.Frontiers in pharmacology · 2024Article
- Oxidative Mechanisms and Cardiovascular Abnormalities of Cirrhosis and Portal Hypertension.International journal of molecular sciences · 2023Review
- Selective gene expression profiling contributes to a better understanding of the molecular pathways underlying the histological changes observed after RHMVL.BMC medical genomics · 2022Article
- Antioxidant Effects of Irisin in Liver Diseases: Mechanistic Insights.Oxidative medicine and cellular longevity · 2022Review
- Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations.Gastro hep advances · 2022Review
- Review
- Oxidative Stress Linked Organ Lipid Hydroperoxidation and Dysregulation in Mouse Model of Nonalcoholic Steatohepatitis: Revealed by Lipidomic Profiling of Liver and Kidney.Antioxidants (Basel, Switzerland) · 2021Article
- Article
- Walnut Consumption Induces Tissue-Specific Omega-6/Omega-3 Decrease in High-Fructose-Fed Wistar Rats.ACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver disease constitutes a growing public health issue worldwide, with no safe and effective enough treatment clinical scenarios. The present review provides an overview of the current knowledge regarding advanced chronic liver disease (ACLD), focusing on the major contributors of its pathophysiology: inflammation, oxidative stress, fibrosis and portal hypertension. We present the benefits of supplementation with docosahexaenoic acid triglycerides (TG-DHA) in other health areas as demonstrated experimentally, and explore its potential as a novel nutraceutical approach for the treatment of ACLD and portal hypertension based on published pre-clinical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.